Institute for Systems Biology
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Jul 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Methods for Identifying Treatment Targets Based on Multiomics Data (US 11,657,895) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Methods to identify antituberculosis compounds (US 10,472,687) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Nov 10, 2027The maintenance fee for Method of detecting phosphorylation state of beta-catenin (US 9,334,315) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 24, 2026
- Sep 9 US 8,828,963 Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,106,166 | Antibodies that bind specifically to phosphorylated β-catenin In force · USPTO record | In force | USPTO record | |
| US 8,425,878 | New Plasma Membrane Biomarkers Preferentially Expressed in Pancreatic Beta Cells Useful in Imaging or Targeting Beta Cells In force · High confidence | In force | High confidence | |
| US 9,002,652 | Methods for identifying and using organ-specific proteins in blood In force · High confidence | In force | High confidence | |
| US 9,334,315 | Method of detecting phosphorylation state of beta-catenin In force · USPTO record | In force | USPTO record | |
| US 8,748,101 | METHODS, COMPOSITIONS, AND DEVICES UTILIZING MicroRNA TO DETERMINE PHYSIOLOGICAL CONDITIONS In force · High confidence | In force | High confidence | |
| US 10,472,687 | Methods to identify antituberculosis compounds In force · USPTO record | In force | USPTO record | |
| US 12,201,679 | Epitope-targeted peptide immunostimulants In force · USPTO record | In force | USPTO record | |
| US 11,414,460 | KRAS-specific capture agents, compositions, and methods of making and using In force · USPTO record | In force | USPTO record | |
| US 11,657,895 | Methods for Identifying Treatment Targets Based on Multiomics Data In force · High confidence | In force | High confidence | |
| US 12,247,009 | Crosslinkers for mass spectrometric identification and quantitation of interacting peptides In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 12: 6 patents in force now held by others · 32 lapsed for an unpaid fee · 23 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 8 abandoned · 32 no status recorded